Profile data is unavailable for this security.
About the company
Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company operates through one business segment, which is the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The Company focuses also on development of gene therapy for the treatment of LAMA2 (Laminin Subunit Alpha 2) deficient congenital muscular dystrophy (CMD). Santhera operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.
- Revenue in CHF (TTM)103.38m
- Net income in CHF54.78m
- Incorporated2002
- Employees46.00
- LocationSanthera Pharmaceuticals Holding AGHohenrainstrasse 24PRATTELN 4133SwitzerlandCHE
- Phone+41 619068950
- Fax+41 619068951
- Websitehttps://www.santhera.com/